These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 9146775

  • 41. Morning versus evening dosing of lansoprazole 30 mg daily on twenty-four-hour intragastric acidity in healthy subjects.
    Fraser AG, Sawyerr AM, Hudson M, Smith MS, Pounder RE.
    Aliment Pharmacol Ther; 1996 Aug; 10(4):523-7. PubMed ID: 8853755
    [Abstract] [Full Text] [Related]

  • 42. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
    Shimatani T, Inoue M, Kuroiwa T, Xu J, Mieno H, Nakamura M, Tazuma S.
    Clin Pharmacol Ther; 2006 Jan; 79(1):144-52. PubMed ID: 16413249
    [Abstract] [Full Text] [Related]

  • 43. Effects of different antisecretory drugs on gastric potential difference in the rat: comparison with sucralfate.
    Coruzzi G, Coppelli G, Frati P, Bertaccini G.
    Pharmacol Res; 1998 Dec; 38(6):469-73. PubMed ID: 9990656
    [Abstract] [Full Text] [Related]

  • 44. Twenty-four-hour intragastric acidity: 300 mg ranitidine b.d., 20 mg omeprazole o.m., 40 mg omeprazole o.m. vs. placebo.
    Houben GM, Hooi J, Hameeteman W, Stockbrügger RW.
    Aliment Pharmacol Ther; 1995 Dec; 9(6):649-54. PubMed ID: 8824652
    [Abstract] [Full Text] [Related]

  • 45. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole.
    Adachi K, Katsube T, Kawamura A, Takashima T, Yuki M, Amano K, Ishihara S, Fukuda R, Watanabe M, Kinoshita Y.
    Aliment Pharmacol Ther; 2000 Oct; 14(10):1259-66. PubMed ID: 11012469
    [Abstract] [Full Text] [Related]

  • 46. Effects of ranitidine, famotidine, pantoprazole, and omeprazole on intragastric pH in dogs.
    Bersenas AM, Mathews KA, Allen DG, Conlon PD.
    Am J Vet Res; 2005 Mar; 66(3):425-31. PubMed ID: 15822586
    [Abstract] [Full Text] [Related]

  • 47. [Effects of lansoprazole on indomethacin-induced gastric bleeding and mucosal lesions in rats].
    Murakami I, Asano S, Yukishige K, Nagaya H, Satoh H, Inatomi N.
    Nihon Yakurigaku Zasshi; 1996 Dec; 108(6):323-32. PubMed ID: 9017686
    [Abstract] [Full Text] [Related]

  • 48. Effects of lansoprazole on gastric ulcer healing and mucin content.
    Komuro Y, Ishii K, Miyake Y, Tanabe S, Oida M, Saigenji K.
    J Clin Gastroenterol; 1995 Dec; 20 Suppl 2():S47-51. PubMed ID: 7594339
    [Abstract] [Full Text] [Related]

  • 49. A comparison of rabeprazole, lansoprazole, and ranitidine for improving preoperative gastric fluid property in adults undergoing elective surgery.
    Nishina K, Mikawa K, Takao Y, Shiga M, Maekawa N, Obara H.
    Anesth Analg; 2000 Mar; 90(3):717-21. PubMed ID: 10702463
    [Abstract] [Full Text] [Related]

  • 50. Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease.
    Janczewska I, Sagar M, Sjöstedt S, Hammarlund B, Iwarzon M, Seensalu R.
    Scand J Gastroenterol; 1998 Dec; 33(12):1239-43. PubMed ID: 9930385
    [Abstract] [Full Text] [Related]

  • 51. Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups.
    Shirai N, Furuta T, Xiao F, Kajimura M, Hanai H, Ohashi K, Ishizaki T.
    Aliment Pharmacol Ther; 2002 Apr; 16(4):837-46. PubMed ID: 11929404
    [Abstract] [Full Text] [Related]

  • 52. Pharmacodynamic modeling of lansoprazole using an indirect irreversible response model.
    Puchalski TA, Krzyzanski W, Blum RA, Jusko WJ.
    J Clin Pharmacol; 2001 Mar; 41(3):251-8. PubMed ID: 11269565
    [Abstract] [Full Text] [Related]

  • 53. [Submicroscopic aspects of the mechanism of inhibitors of H+/K+-ATPase in gastric parietal cells].
    Morozov IA.
    Eksp Klin Gastroenterol; 2002 Mar; (3):94-100, 122. PubMed ID: 12353402
    [Abstract] [Full Text] [Related]

  • 54. Lansoprazole: an update of its place in the management of acid-related disorders.
    Matheson AJ, Jarvis B.
    Drugs; 2001 Mar; 61(12):1801-33. PubMed ID: 11693467
    [Abstract] [Full Text] [Related]

  • 55. [Effect of a proton pump inhibitor AG-1749 (lansoprazole) on intragastric pH: 24-hour intragastric pH monitoring].
    Kihira K, Yoshida Y, Kasano T, Taniguchi Y, Sato K, Kimura K, Hirose M, Koyama H.
    Nihon Shokakibyo Gakkai Zasshi; 1991 Mar; 88(3):672-80. PubMed ID: 1646341
    [Abstract] [Full Text] [Related]

  • 56. The effects of low doses of ranitidine on intragastric acidity in healthy men.
    Wyeth JW, Pounder RE, Sercombe JC, Snell CC.
    Aliment Pharmacol Ther; 1998 Mar; 12(3):255-61. PubMed ID: 9570260
    [Abstract] [Full Text] [Related]

  • 57. Control of intragastric pH with omeprazole 20 mg, omeprazole 40 mg and lansoprazole 30 mg.
    Katz PO, Xue S, Castell DO.
    Aliment Pharmacol Ther; 2001 May; 15(5):647-52. PubMed ID: 11328258
    [Abstract] [Full Text] [Related]

  • 58. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors.
    Xue S, Katz PO, Banerjee P, Tutuian R, Castell DO.
    Aliment Pharmacol Ther; 2001 Sep; 15(9):1351-6. PubMed ID: 11552905
    [Abstract] [Full Text] [Related]

  • 59. Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD.
    Howden CW, Ballard ED, Koch FK, Gautille TC, Bagin RG.
    J Clin Gastroenterol; 2009 Apr; 43(4):323-6. PubMed ID: 18758373
    [Abstract] [Full Text] [Related]

  • 60. Lansoprazole regimens that sustain intragastric pH > 6.0: an evaluation of intermittent oral and continuous intravenous infusion dosages.
    Metz DC, Amer F, Hunt B, Vakily M, Kukulka MJ, Samra N.
    Aliment Pharmacol Ther; 2006 Apr 01; 23(7):985-95. PubMed ID: 16573801
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.